Peptide-dependent vectors have received interest for their specificity in binding to receptors overexpressed in breast cancer cells, probably overcoming problems relevant to low internalization. Through these clinical trials, researchers are not only uncovering new treatment options but are paving the way for personalized medicine, exactly where